Advertisement

Combining Pharmacological and Psychological Treatments for Binge Eating Disorder: Current Status, Limitations, and Future Directions

  • Carlos M. GriloEmail author
  • Deborah L. Reas
  • James E. Mitchell
Eating Disorders (C Grilo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Eating Disorders

Abstract

Binge eating disorder (BED) is characterized by recurrent binge eating and marked distress about binge eating without the extreme compensatory behaviors for weight control that characterize other eating disorders. BED is prevalent, associated strongly with obesity, and is associated with heightened levels of psychological, psychiatric, and medical concerns. This article provides an overview of randomized controlled treatments for combined psychological and pharmacological treatment of BED to inform current clinical practice and future treatment research. In contrast to the prevalence and significance of BED, to date, limited research has been performed on combining psychological and pharmacological treatments for BED to enhance outcomes. Our review here found that combining certain medications with cognitive behavioral therapy (CBT) or behavioral weight loss (BWL) interventions produces superior outcomes to pharmacotherapy only but does not substantially improve outcomes achieved with CBT/BWL only. One medication (orlistat) has improved weight losses with CBT/BWL albeit minimally, and only one medication (topiramate) has enhanced reductions achieved with CBT in both binge eating and weight. Implications for future research are discussed.

Keywords

Binge eating disorder Obesity Cognitive behavioral therapy Behavioral weight loss Medication Pharmacotherapy 

Notes

Acknowledgments

The authors thank Dr. Scott Crow and Dr. Michael Devlin for their reviews and constructive comments on this manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors report that they have no financial or other conflicts of interest with respect to the content of this paper. No academic, pharmaceutical, or industry entity of any kind influenced this review study or the preparation of this report in any manner.

Dr. Carlos M. Grilo reports grants from the National Institutes of Health, consulting fees from Shire and Sunovion, honoraria from the American Psychological Association and from universities and scientific conferences for grand rounds and lecture presentations, speaking fees for various CME activities, and consulting fees from American Academy of CME, Vindico Medical Education CME, General Medical Education CME, Medscape/WebMD Education CME, and book royalties from Guilford Press and from Taylor Francis Publishers.

Dr. Deborah L. Reas has no financial or other conflicts of interest to disclose.

Dr. James E. Mitchell reports grants from the National Institutes of Health and book royalties from Guilford Press, Routledge Press, and American Psychiatric Press.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding

Preparation of this paper was supported, in part, by National Institutes of Health (NIH) Grant K24 DK070052 (Grilo). The NIH had no role or influence on the content of the paper nor does the content reflect the views of the NIH.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.Google Scholar
  2. 2.
    Hudson JI, Hiripi E, Pope Jr HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61:348–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, et al. The prevalence and correlates of binge eating disorder in the World Health Organization world mental health surveys. Biol Psychiatry. 2013;73:904–14.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Marques L, Alegria M, Becker AE, Chen CN, Fang A, Chosak A, et al. Comparative prevalence, correlates of impairment, and service utilization for eating disorders across US ethnic groups: implications for reducing ethnic disparities in health care access for eating disorders. Int J Eat Disord. 2011;44:412–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Grilo CM, Masheb RM, White MA. Significance of overvaluation of shape/weight in binge-eating disorder: comparative study with overweight and bulimia nervosa. Obesity. 2010;18:499–504.CrossRefPubMedGoogle Scholar
  6. 6.
    Hudson J, Lalonde JK, Berry JM, Pindyck LJ, Bulik CM, Crow SJ, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry. 2006;63:313–9.CrossRefPubMedGoogle Scholar
  7. 7.
    APA. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington: American Psychiatric Publishing; 1994.Google Scholar
  8. 8.
    Devlin MJ. Binge-eating disorder and obesity. A combined treatment approach. Psychiatr Clin N Am. 2001;24:325–35.CrossRefGoogle Scholar
  9. 9.
    NICE. Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa, and related eating disorders. NICE Clinical Guideline No. 9. London, 2004.Google Scholar
  10. 10.
    Iacovino JM, Gredysa DM, Altman M, Wilfley DE. Psychological treatments for binge eating disorder. Curr Psychiatr Rep. 2012;14:432–46.CrossRefGoogle Scholar
  11. 11.
    Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol. 2007;62:199–216.CrossRefPubMedGoogle Scholar
  12. 12.
    Wilson GT, Zandberg LJ. Cognitive-behavioral guided self-help for eating disorders: effectiveness and scalability. Clin Psychol Rev. 2012;32:343–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry. 2010;67:94–101.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hilbert A, Bishop ME, Stein RI, Tanofsky-Kraff M, Swenson AK, Welch RR, et al. Long-term efficacy of psychological treatments for binge eating disorder. Br J Psychiatry. 2012;200:232–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Grilo CM, Masheb RM, Wilson GT, Gueorguieva R, White MA. Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. J Consult Clin Psychol. 2011;79:675–85.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Brownley KA, Peat CM, La Via M, Bulik CM. Pharmacological approaches to the management of binge eating disorder. Drugs. 2015;75:9–32.CrossRefPubMedGoogle Scholar
  17. 17.
    McElroy SL, Guerdjikova AI, Mori N, Keck PE. Psychopharmacologic treatment of eating disorders: emerging findings. Curr Psychiatr Rep. 2015;17:35.CrossRefGoogle Scholar
  18. 18.
    Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity. 2008;16:2024–38.CrossRefPubMedGoogle Scholar
  19. 19.
    Reas DL, Grilo CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015;16:1463–78.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Agras WS, Telch CF, Arnow B. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder: an additive design. Behav Ther. 1994;25:225–38.CrossRefGoogle Scholar
  21. 21.
    Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord. 1999;26:231–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Ricca V, Mannucci E, Mezzani B, Moretti S, Di BM, Bertelli M, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 2001;70:298–306.CrossRefPubMedGoogle Scholar
  23. 23.
    Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS, Wolk S, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res. 2005;13:1077–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity. 2007;15:1702–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13:1701–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005;57:1193–201.CrossRefPubMedGoogle Scholar
  27. 27.
    Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57:301–9.CrossRefPubMedGoogle Scholar
  28. 28.••
    Grilo CM, Crosby RD, Wilson GT, Masheb RM. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder. J Consult Clin Psychol. 2012;80:1108–13. RCT reported 12-month follow-up data after completing and discontinuing 16-week acute treatments with fluoxetine, CBT + fluoxetine, or CBT + placebo. Findings indicate the significantly superior specific durability of CBT relative to fluoxetine and that fluxotine does not enhance CBT outcomes after treatment completion.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.••
    Claudino AM, de Oliveira IR, Appolinario JC, Cordas TA, Duchesne M, Sichieri R, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324–32. RCT reported that the addition of topiramate to CBT enhanced binge eating and weight loss outcomes in patients with BED at post-treatment.CrossRefPubMedGoogle Scholar
  30. 30.
    Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C. Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. Psychiatry. 2009;6:23–8.PubMedPubMedCentralGoogle Scholar
  31. 31.••
    Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013;51:167–75. RCT performed in a community-based setting serving Latinos reported that adding orlistat to BWL produced greater weight loss than adding placebo among obese patients without BED but not among those with BED. 50 % of BED patients maintained binge-abstinence at 6-month follow-ups; despite such improvements, BED was a negative predictor of some treatment outcomes.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, et al. Treatment of binge eating in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication. Behav Res Ther. 2014;58:1–9.CrossRefPubMedGoogle Scholar
  33. 33.
    National Institute of Mental Health; University of Virginia. Adding guided self-help group therapy to the Alli weight loss program in treating binge eating disorder. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2000 [cited 2016 Feb 2). Available from: https://clinicaltrials.gov/ct2/show/NCT00601354?term=NCT00601354&rank=1.
  34. 34.
    National Institute of Mental Health; University of Virginia. A comparison of methylphenidate and cognitive behavioural therapy for the treatment of binge eating disorder. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2000 [cited 2016 Feb 2). Available from: https://clinicaltrials.gov/ct2/show/NCT01921582.
  35. 35.
    National Institute of Mental Health; University of Virginia. Treatment of obesity and binge eating: behavioral weight loss versus stepped care. In: ClinicalTrials.gov [Internet]. Bethesda (MD). National Library of Medicine (US); 2002 [cited 2016 Feb 2). Available from: https://clinicaltrials.gov/ct2/show/NCT00829283.
  36. 36.
    Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165:51–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Mitchell JE, Fletcher L, Harrison K, Mussell MP, Seim H, Crosby RD, et al. The relative efficacy of fluoxetine and manual-based self-help in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol. 2001;21:298–304.CrossRefPubMedGoogle Scholar
  38. 38.
    Walsh BT, Fairburn CG, Mickley DE, Sysko R, Parides MK. Treatment of bulimia nervosa in a primary care setting. Am J Psychiatry. 2004;161:556–61.CrossRefPubMedGoogle Scholar
  39. 39.
    McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65:1463–9.CrossRefPubMedGoogle Scholar
  40. 40.••
    McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatr. 2015;72:235–46. Large multi-site RCT reported short-term efficacy of 50 and 70 mg LDX relative to placebo at 11-weeks in patients with moderate-to-severe BED.CrossRefGoogle Scholar
  41. 41.••
    McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2015. doi: 10.1038/npp.2015.275. Two large phase 3 RCTs reported short-term efficacy of 50–70 mg/day dosing of LDX relative to placebo in patients with moderate-to-severe BED. LDX associated with binge abstinence rates of 40 and 36% in the two trials at the 11-week post-treatment evaluation. These data supported FDA approval of this medication for BED.PubMedPubMedCentralGoogle Scholar
  42. 42.••
    Grilo CM, Masheb RM, Crosby RD. Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder. J Consult Clin Psychol. 2012;80:897–906. Important methodological paper demonstrating analyses of predictors/moderators of treatment outcomes. Findings suggested that overvaluation of shape/weight and negative affect are significant moderators of treatment outcome; patients with these characteristics fare better in CBT and in fluoxetine treatments.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Carlos M. Grilo
    • 1
    Email author
  • Deborah L. Reas
    • 2
    • 3
  • James E. Mitchell
    • 4
    • 5
  1. 1.Department of Psychiatry, School of MedicineYale UniversityNew HavenUSA
  2. 2.Regional Department for Eating Disorders, Division of Mental Health and AddictionOslo University HospitalOsloNorway
  3. 3.Department of Psychology, Faculty of Social SciencesUniversity of OsloOsloNorway
  4. 4.Neuropsychiatric Research InstituteFargoUSA
  5. 5.Department of Clinical Neuroscience, School of Medicine and Health SciencesUniversity of North DakotaFargoUSA

Personalised recommendations